ANI Pharmaceuticals Inc
ANIP
Market Cap$2.03B
Close$
$-54.62
157.3% downside
Current Fair Value
157.3% downsideOvervalued by 157.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.03 Billion |
|---|---|
| Enterprise Value | $2.13 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.04 |
| Beta | 0.61 |
| Outstanding Shares | 19,834,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -168.12 |
|---|---|
| PEG | 38.38 |
| Price to Sales | 2.58 |
| Price to Book Ratio | 4.33 |
| Enterprise Value to Revenue | 2.85 |
| Enterprise Value to EBIT | 405.22 |
| Enterprise Value to Net Income | -194 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.74 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About ANI Pharmaceuticals Inc
CEO: Patrick Walsh ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include ...